Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.74 |
| ▸ | CCR3 | P51677 | 4/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.73 |
| ▸ | NAAA | Q02083 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.63 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.63 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.63 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.63 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.63 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.63 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.62 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.62 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.62 |
| ▸ | HTR7 | P34969 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29244363 | 1.00 | KCNH2 (0.74) | KCNH2CCR3SIGMAR1NAAASLC6A2 | |
| SCHEMBL29244366 | 0.98 | CCR3 (0.75) | KCNH2CCR3SIGMAR1NAAASLC6A2 | |
| Bromide SCHEMBL7253360 | 0.97 | CCR3 (0.73) | KCNH2CCR3SIGMAR1NAAASLC6A2 | |
| SCHEMBL7247832 | 0.94 | CCR3 (0.72) | KCNH2CCR3SIGMAR1SLC6A2SLC6A4 | |
| Bromide SCHEMBL7249670 | 0.92 | CCR3 (0.70) | KCNH2CCR3SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL7248849 | 0.87 | CCR3 (0.73) | KCNH2CCR3SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL8091672 | 0.86 | SIGMAR1 (0.97) | KCNH2CCR3SIGMAR1NAAASLC6A2 | |
| SCHEMBL18764215 | 0.85 | CARM1 (0.77) | KCNH2CCR3SIGMAR1NAAASLC6A2 | |
| SCHEMBL12040797 | 0.85 | KCNH2 (1.00) | KCNH2CCR3SIGMAR1NAAASLC6A2 | |
| SCHEMBL29244381 | 0.85 | KCNH2 (0.74) | KCNH2CCR3SIGMAR1NAAASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144319-A1 | Subtype-selective NMDA receptor ligands and the use thereof | BIGGE CHRISTOPHER F (US) | 2003-07-31 | — | — | US | disclosed |
| US-6534522-B2 | E.g.,N-((4-amino-3-nitrophenoxy)ethyl)-1,2,3,4-tetrahydro -isoquinoline; stroke; antiischemic agents; CNS trauma, hyperglycemic agents; surgery; neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis | WARNER-LAMBERT COMPANY | 2003-03-18 | — | — | US | disclosed |
| US-20010051633-A1 | Subtype-selective NMDA receptor ligands and the use thereof | BIGGE CHRISTOPHER F (US) | 2001-12-13 | — | — | US | disclosed |
| US-6218404-B1 | THERAPY AND PROPHYLAXIS OF NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CNS TRAUMA, HYPOGLYCEMIA AND SURGERY, NEURO-DEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, HUNTINGTON'S DISEASE | WARNER-LAMBERT CO. | 2001-04-17 | — | — | US | disclosed |
| WO-1997023458-A1 | SUBTYPE-SELECTIVE NMDA RECEPTOR LIGANDS AND THE USE THEREOF | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144319-A1 | Subtype-selective NMDA receptor ligands and the use thereof | OPRK1, OPRD1, OPRL1 | KCNH2 615/4885CCR3 3050/4885SIGMAR1 664/4885 |
| US-20010051633-A1 | Subtype-selective NMDA receptor ligands and the use thereof | OPRK1, OPRD1, OPRL1 | KCNH2 615/4885CCR3 3050/4885SIGMAR1 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.